Covid-19 vaccine candidate in the country.DCGI VG Somani, in a letter to SII, has said that the institute's reply has been "carefully examined" as also the recommendations of the DSMB in India and in UK."You (SII) may recommence the clinical trial dated August 2, 2020, as recommended by the Data Safety Monitoring Board (DSMB), India as per already approved protocol and the provisions laid down under New Drugs and Clinical Trials Rules, 2019 subject to the conditions mentioned which are to be scrupulously followed such as extra care during screening, additional information in the informed consent and close monitoring for similar events during the study follow-up," the letter said as reported by news agency ANI.The DCGI has also asked SII to.